today. productive Cellectis. everyone Good year Arthur. you, us thank you was a joining morning XXXX for Thank for and
become the are full relates made biopharmaceutical a we progress end-to-end to evolve to our We company. it and cell corporate therapy milestones as gene of as proud we've
of front plants with supply products' of that gives the on our control manufacturing our escalating us and candidate. line. We We completed have doses quality progressed clinical product and
We innovate. continue to
it working clinic product, first XXXX. have bring duel-targeted the to on to plan We in UCART been our UCARTXXxXX, and
It to through is to Cellectis T have been have partnered outside secure. plans, had resolved. future issues that platform TALEN financial Regulatory takes able core dual of paused of CAR is cell our cash issues Cellectis XXXX, none been business We clear our in some leverage that programs with early valuable to position the on therapy due technology. but allogeneic XXXX. these not Based our just field area. of are us And opportunities our TALEN our to term provide our
touch Medical on progress. First, I Brownstein, additional Chief Carrie will some details give will later. clinical of the Officer, our
preliminary BALLI-XX highest level regimen preconditioning right dose relapsed that refractory into of tolerated showed B in cancers. American running the different regimen or or expansion BALLI-XX lymphoblastic and promoted encouraging from the as At and provides our and was in December These alemtuzumab of X. fludarabine, at Society acute the we're forms our annual us activity and strong the sold UCARTXX XXXX, meeting efficacy in includes that we trials three results enrolling have refractory released Currently, confidence that moving with of patients in data B the we safety These received of dose our lymphodepletion alemtuzumab patients evaluating cyclophosphamide so leukemia. trial in of relapsed direction. UCARTXX held with lymphoblastic Hematology leukemia. well We are hematological patients patients cell the clinical trial, far,
the cancer to added another regimen AMELI-XX trial, also in We clinical alemtuzumab in leukemia. acute preconditioning blood myeloid
on AMELI-XX, ambitious ongoing product ability our patient our escalation BALLI-XX, multicenter trial new focused clinic, XXXX, the into in to three clinical program, dose recruitment we're – moving our So, and in development confident execute MELANI-XX. into
new for cash our We XXXX. candidate, roadmap, patients refractory also QX takes lymphoma. relapsed runway plan or with our into UCARTXXxXX, product to non-Hodgkin's this us new for file IND With a
the progress in end-to-end companies. made XXXX, processes. manufacturing one therapy now made the cell its Back and providing and in turn decision product gene cell Let's and with over internalize becoming XXXX. we the manufacturing. independence a have stronghold to the of In few gene candidate, meaningfully Cellectis towards the company Cellectis its therapeutics made therapy to of
that We been are has XXXX. thrilled goal to this achieved in say
produce sites our plasmid Our and recombinant our RNA, and produce Paris, we libraries, both our lentiviruses. operational. fully France North Raleigh, Carolina two DNA, own own type vectors, in manufacturing messenger are now AAVs cell two of We
our produce up T CAR to product. allogenic We are own clinical grade set
half clinical initiate and derisks already lymphoma. to very in commercial I supplies. reasons. supplies file candidates. the fact, the in-house in clinical exciting UCARTXXxXX becoming in of patients the This two self-sufficient new trial. plan its and clinical trial to Raleigh manufactured of least is dependence plan These positioned product are second candidate, market. In UCARTXX bumps lymphoma the dosing non-Hodgkin's is of BALLI-XX in This of suppliers. in XXXX, our non-Hodgkin's mentioned in a removes success on UCARTXXxXX, to We're on road. into This to an capitalize with IND outside reduces we product at a Cellectis our product for passed
candidate in T is validated The targets be enter First, developed designed CAR clinical manufactured Cellectis malignancy. in-house candidate also our first to It first cell duel-allogenic to has B potentially product product is hit in-house, and designed the in-house. UCARTXXxXX two trial. will
treated Allogene technology XXXX. reported of remains to beyond of important on X, targeting product a base source year, the Cellectis to our refractory removed that cell clinical the edited partner, and this enrolling multiple also myeloma. earlier the determined BCMA or and B Drug that CDXX UCART which TALEN that Allogene this was the Servier, ALLO-XXXA goes chromosomal single We clinical has which and has activities studies as Administration gene cells. pipeline began investigation, revenues. unrelated after relapsed the clear studies cell future resumed or clinical announced clinical of allogenic that, trials, in has Allogene of to Food power B it overcrowded on the clinical will and partnered targeting for hold on for validation metastatic on our resume carcinoma, January Allogene in want on ALLO-XXX patients CDXX. with old States United patient a candidate, activities products. addition, was ALLO-XXX, and it In its cells. In of believe announced now ALLO-XXX of month. announced edited detected editing it CDXX targeting all CDXX to about the it TALEN word that TALEN on Allogene's T announced activities their abnormality say real Allogene some was that October gene antigen product has resumed cells it's a gene I crowded advanced is UCARTXXxXX CAR renal alternative
the in T to is collaboration Annual or or pending initiate December in safe intent XXXX, American XXXX durable approved that mid-year therapy XXXX Servier of to to ALLO-XXXA support and and ALLO-XXX Society patients its refractory Allogene the on and X non-Hodgkin's on in Allogene trial the discussion. Phase FDA ALPHA lymphoma. alternatives cell large announced Meeting relapsed of refractory the reported data CAR autologous with lymphoma a B from with to clinical ALLO-XXXA promises continued pivotal track relapsed commence be results Hematology During ALPHAX to in
new of editing collaboration continued opportunity. and TALEN of front, Cytovia single-digit entered cash CAR satisfaction to sales by provide strategic Therapeutics. million with cells, company provides type joint include type of December XXst, development to condition TALEN In met. such and/or business agreement a with discussion with the The of NK be the conditions and the highlights up editing that the in utility and in $XX of February another of as either of new on expanded on TALEN selective development, system different to milestone XXXX, into the China to stake edited Therapeutics with cell gene products XXXX. modality research depending include T payments is in all totaling the CAR extension equity and $XXX Cytovia technology collaboration series Cellectis and us with gene in develop regulatory application. deadline Cytovia. target for XXXX, On product million by a net Cytovia and regarding partnerships for Iovance also expanded by partnered the In Biotherapeutics, we Cytovia IPS-NK development sales Financial for November royalty collaboration gene development entity, the certain Allogene choice CytoLynx that therapy cell Cytovia therapy signed, After have term of a payment venture to tumors. of commercialized we
top We committee general talent. team have management expanded also board and with our
committee executive background to highly with public who a like Chief Firstly, to leveraging cell company of co-founder companies clinical next clinical he financing our the team, and chief we corporate He and Officer. moment is appointed oncology global Welcome comes extensive to in Bing gene Refuge biology experience us biotechnology welcome Bing our trials. Cellectis. officer. Biotechnologies, biotechnology extensive Bing. would Cellectis stage of the to development recently therapy accomplished in new finance executive Bing was including synthetic the our will in companies finance. industry, enter our Financial stage Dr. take in from engineering, as this experience to executive where brings global Cellectis a and biotech be to Bing's Wang, I critical
[indiscernible] November observer Research clear an XXXX. company's themselves. medical place products that Head multiple board Bergstrom Dr. and of to at production candidate. brings of XX appointed stays of Therapeutics, as elements biology with serves precision director Donald Cellectis have on to industry the years Dr. prove the and the in already Secondly, medicine many the its Development experience Relay transform focused of in as of cellular opportunities needs clinical Cellectis as him the biopharmaceutical and in Bergstrom company. clinical plan of in We
to We we forward that in push have continue future. and future the to resources invested have in the
Carrie, to product would an turn the Medical preclinical clinical give to like trials Carrie I call Chief overview our Brownstein, over our please and Dr. ahead. go to sponsored three pipeline. of Officer, Now,
